Æ®·½ÇǾî(Tremfya) ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® ¸®Æ÷Æ® : ¿ëµµº°(ÇöóÅ© °Ç¼±, °Ç¼±¼º °üÀý¿°, ±âŸ), À¯Åë ä³Îº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
Tremfya Market Size, Share, Trends, Industry Analysis Report By Application [Plaque Psoriasis, Psoriatic Arthritis (PsA), Others], By Distribution Channel, By Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1786937
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 5,945,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,344,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,743,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ¼¼°èÀÇ Æ®·½ÇÇ¾î ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 79¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ ¸®Æ÷Æ®´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ °üÇÑ ºÐ¼®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

Æ®·½ÇÇ¾î ½ÃÀåÀº »ý¹°Á¦Á¦ÀÎ ±¸¼¿·ç¸¿ÀÇ ¼¼°è ÆÇ¸Å ¹× À¯ÅëÀÌ ÁÖ¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ Ã·´Ü Ä¡·áÁ¦´Â ¿°Áõ ¹ÝÀÀ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¸é¿ª°è ´Ü¹éÁúÀÎ ÀÎÅÍ·ùŲ 23(IL-23)À» ƯÀÌÀûÀ¸·Î Ç¥ÀûÀ¸·Î »ï½À´Ï´Ù. Æ®·½ÇǾî´Â ÁÖ·Î Áߵ¿¡¼­ ÁßÁõÀÇ ½É»ó¼º °Ç¼±, Ȱµ¿¼º °üÀý¿°¼º °Ç¼± µî ¸¸¼ºÁúȯÀÇ °ü¸®¿¡ »ç¿ëµÇ¸ç, ¿°ÁõÀ» ¾ïÁ¦Çϰí ȯÀÚÀÇ Áõ»óÀ» °³¼±ÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÕ´Ï´Ù. ÃÖ±Ù¿¡´Â Áߵ¿¡¼­ ÁßÁõÀÇ È°µ¿¼º ±Ë¾ç¼º ´ëÀå¿°À̳ª Å©·Ðº´¿¡µµ »ç¿ëµÇ¾î ±× ¿ëµµ¿Í ȯÀÚ ¹üÀ§°¡ ³Ð¾îÁö°í ÀÖ½À´Ï´Ù.

Æ®·½ÇÇ¾î ½ÃÀåÀÇ ¼ºÀåÀº ÀÌ·¯ÇÑ ¸¸¼º ¿°Áõ¼º ÁúȯÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÏ´Â ¹Ù°¡ Å®´Ï´Ù. °Ç¼±À̳ª °üÀý¿°¼º °Ç¼±°ú °°Àº ÁúȯÀ¸·Î Áø´ÜÀ» ¹Þ´Â ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀ̰í Àå±âÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚÀÇ Áõ»ó ¹× »îÀÇ Áú °³¼±¿¡ ÀÖÀ¸¸ç, Ź¿ùÇÑ È¿´ÉÀ» º¸ÀÌ´Â Æ®·½ÇǾîÀÇ °­·ÂÇÑ ÀÓ»ó ÇÁ·ÎÆÄÀÏÀº ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. Áö¼ÓÀûÀÎ °á°ú¸¦ °¡Á®¿À°í °æ¿ì¿¡ µû¶ó¼­´Â Áúº´ÀÇ ÁøÇàÀ» ¾ïÁ¦ÇÏ´Â ´É·ÂÀº °í±Þ Ä¡·á ¼Ö·ç¼ÇÀ» ã´Â ÀÇ·áÁø°ú ȯÀڵ鿡°Ô ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Æ®·½ÇÇ¾î ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¿ëµµº°·Î´Â 2024³â Æ®·½ÇÇ¾î ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÑ °ÍÀº ½É»ó¼º °Ç¼± ºÎ¹®À̾ú½À´Ï´Ù. ÀÌ´Â ÁÖ·Î ½É»ó¼º °Ç¼±ÀÌ Àü ¼¼°è¿¡¼­ ¸¹Àº »ç¶÷µé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, Æ®·½ÇǾ Åõ¸íÇÑ ÇǺΠ¶Ç´Â °ÅÀÇ Åõ¸íÇÑ ÇǺθ¦ ¾òÀ» ¼ö ÀÖ´Ù´Â °­·ÂÇÑ °á°ú¸¦ º¸¿©Áá±â ¶§¹®ÀÔ´Ï´Ù.

À¯Åë ä³Îº°·Î´Â º´¿ø ¾à±¹ ºÎ¹®ÀÌ 2024³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â º´¿ø ³»¿¡¼­ ÀÌ·ç¾îÁö´Â °æ¿ì°¡ ¸¹Àº »ý¹°Á¦Á¦ÀÇ Àü¹®ÀûÀÎ Ãë±Þ ¹× Åõ¿©ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ º¹ÀâÇÑ Ä¡·á¸¦ ó¹æÇÏ´Â Àü¹®Àǰ¡ º´¿ø¿¡ ±â¹ÝÀ» µÎ°í ÀÖ´Â °æ¿ì°¡ ¸¹±â ¶§¹®ÀÔ´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ÇØ´ç Áö¿ªÀÇ ³ôÀº Áúº´ À¯º´·ü, ÷´Ü »ý¹°Á¦Á¦ Ä¡·á¸¦ Áö¿øÇÒ ¼ö ÀÖ´Â ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ°í, Çõ½ÅÀûÀÌ°í ºñ¿ëÀÌ ¸¹ÀÌ µå´Â Ä¡·á¹ý¿¡ ´ëÇÑ ÀϹÝÀû ¼ö¿ë ÀÇÁö°¡ ³ô±â ¶§¹®À¸·Î ºÐ¼®µË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Æ®·½ÇǾîÀÇ ½ÅÈï ½ÃÀåÀ¸·Î ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ÀϺΠÁö¿ª¿¡¼­´Â ¸¸¼º ¿°Áõ¼º ÁúȯÀÇ À¯º´·üÀÌ ¿ª»çÀûÀ¸·Î ³·°Ô ÀÎ½ÄµÇ¾î ¿ÔÁö¸¸, µµ½ÃÈ­, »ýȰ¾ç½ÄÀÇ º¯È­, Áø´Ü ´É·ÂÀÇ Çâ»óÀ¸·Î ÀÎÇØ º¸°íµÈ »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Johnson & JohnsonÀÌ ÇöÀç Æ®·½ÇǾîÀÇ Á¦Á¶¾÷üÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå °³¿ä

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°è Æ®·½ÇÇ¾î ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ Æ®·½ÇÇ¾î ½ÃÀå : ¿ëµµº°

Á¦6Àå ¼¼°èÀÇ Æ®·½ÇÇ¾î ½ÃÀå : À¯Åë ä³Îº°

Á¦7Àå ¼¼°èÀÇ Æ®·½ÇÇ¾î ½ÃÀå : Áö¿ª

Á¦8Àå °æÀï ±¸µµ

Á¦9Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global tremfya market size is expected to reach USD 7.99 billion by 2034, according to a new study by Polaris Market Research. The report "Tremfya Market Size, Share, Trends, Industry Analysis Report By Application [Plaque Psoriasis, Psoriatic Arthritis (PsA), Others], By Distribution Channel, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The Tremfya market is centered around the global sales and distribution of guselkumab, a biologic medication. This advanced treatment specifically targets interleukin-23 (IL-23), a protein in the immune system that plays a key role in inflammatory responses. Tremfya is primarily used to manage chronic conditions such as moderate-to-severe plaque psoriasis and active psoriatic arthritis, aiming to reduce inflammation and improve patient symptoms. Recently, its use has expanded to include moderately to severely active ulcerative colitis and Crohn's disease, broadening its application and patient reach.

The Tremfya market growth is largely driven by the increasing global prevalence of these chronic inflammatory diseases. As more people are diagnosed with conditions such as plaque psoriasis and psoriatic arthritis, the demand for effective and long-term treatments continues to rise. Additionally, Tremfya's strong clinical profile, demonstrating significant efficacy in improving symptoms and quality of life for patients, is a major growth factor. Its ability to offer durable outcomes and, in some cases, inhibit disease progression, makes it a preferred option for healthcare providers and patients seeking advanced therapeutic solutions.

Tremfya Market Report Highlights:

By application, the plaque psoriasis segment held the largest share of the Tremfya market in 2024. This is mainly because plaque psoriasis affects a large number of people worldwide, and Tremfya has shown strong results in helping patients achieve clear or almost clear skin.

By distribution channel, the hospital pharmacies segment held the largest share in 2024. This is due to the rising need for specialized handling and administration of biologic drugs, often performed in hospital settings, and the fact that specialists who prescribe these complex treatments are frequently based in hospitals.

By region, North America held the largest share in 2024. This dominance is driven by the high prevalence of target diseases in the region, a well-developed healthcare infrastructure that supports advanced biologic therapies, and a generally higher willingness to adopt innovative and often high-cost treatments. Asia Pacific is an emerging and rapidly expanding market for Tremfya. While the prevalence of chronic inflammatory diseases may historically have been perceived as lower in some parts of this region, increasing urbanization, lifestyle changes, and improved diagnostic capabilities are contributing to a rise in reported cases.

Johnson & Johnson is the current manufacturer of Tremfya.

Polaris Market Research has segmented the Tremfya market report based on application, distribution channel, and region:

By Application Outlook (Revenue - USD Billion, 2020-2034)

Plaque Psoriasis

Psoriatic Arthritis (PsA)

Others

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Tremfya Market Insights

5. Global Tremfya Market, by Application

6. Global Tremfya Market, by Distribution Channel

7. Global Tremfya Market, by Geography

8. Competitive Landscape

9. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â